Tailoring Cost-Effectiveness Modeling Methodologies for Multiple Sclerosis

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in the United Kingdom

Spelman T, Herring WL, Zhang Y, Tempest M, Pearson I, Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand’Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H. 

In this 20-minute presentation, Will Herring, PhD, discusses how to tailor real-world analysis methodologies so that they better fit the needs of cost-effectiveness modeling in multiple sclerosis.

This presentation is based on research sponsored by Biogen using the MSBase registry.